Sun Pharma Reports Strong Q2 FY26 Performance; Innovative Medicines Drive Growth, R&D Pipeline Advancing
Sun Pharma's Q2 FY26 consolidated sales grew 8.6% to ₹144,052 million; EBITDA up 14.9%. Innovative Medicines drove US growth. R&D pipeline advancing with H2 FY26 launches planned.
Quarterly results are crucial for investor assessment. The strong financial performance, strategic shifts in sales mix (innovative vs. generics), and pipeline updates have a significant bearing on the company's future prospects and valuation.
The company reported significant growth in Q2 FY26 consolidated sales and EBITDA. Innovative Medicines sales surpassed generics in the U.S. for the first time, and the India business maintained its number one market position with strong growth. The R&D pipeline is advancing with key launches and filings planned for H2 FY26.
Sun Pharmaceutical Industries Limited has released the transcript of its Q2 FY26 earnings conference call.
Financial Highlights (Consolidated Q2 FY26): * Sales stood at ₹144,052 million, marking an 8.6% growth year-on-year. * Gross margin was 79.3%. * EBITDA reached ₹45,271 million, an increase of 14.9% over Q2 FY25, with an EBITDA margin of 31.3%. * Net profit after tax was ₹31,180 million, up 2.6% year-on-year. * Earnings Per Share (EPS) was ₹13 per share. * Effective tax rate for the quarter was 24.7%. * The company reported a forex gain of ₹4,305 million. * Net cash position remained strong at $2.9 billion (approximately ₹24,147 crore), after accounting for the Checkpoint acquisition and GxMDL case settlement.
Half-Yearly Performance (H1 FY26): * Sales were ₹281,913 million, growing 9.3% over H1 FY25. * Gross margin for the first half was 79.4%. * EBITDA for H1 was ₹88,287 million, a 17% growth, with a margin of 31.2%. * Adjusted net profit for H1 was ₹61,141 million, up 4.1%.
Business Segment Highlights: * Global Innovative Medicines sales increased by 16.4% to $313 million (approximately ₹2,604 crore). For the first time, U.S. sales of Innovative Medicine surpassed generics. * ILUMYA is now commercialized in 35 major markets. * India Formulation sales grew by 11% to ₹47,348 million, contributing 32.9% to total consolidated sales. Sun Pharma is ranked number one in the Indian pharmaceutical market with an 8.3% share as per Pharmarack MAT September 2025, and launched 9 new products in India during the quarter. * Overall U.S. business declined by 4.1% to $496 million (approximately ₹4,124 crore), primarily due to increased competition for certain generic products and lower lenalidomide sales, which offset growth in Innovative Medicines (ILUMYA, CEQUA, ODOMZO). Three new generic products and LEQSELVI were launched in the U.S. during the quarter. * Emerging Markets formulation revenues were $325 million (approximately ₹2,702 crore), up 10.9% (8% in constant currency), driven by broad-based growth in Generics and Innovative Medicines. * Rest of the World formulation revenues were $234 million (approximately ₹1,946 crore), up 17.7%, with growth in both Generics and Innovative Medicines.
R&D and Pipeline Updates: * Consolidated R&D investments for Q2 FY26 were ₹7,827 million, representing 5.4% of sales. * Innovative R&D accounted for 38% of total R&D spend. * The company is awaiting an FDA decision on UNLOXCYT's updated labeling and expects to launch UNLOXCYT in the U.S. in the second half of FY26. * Sun Pharma plans to file the ILUMYA psoriatic arthritis sBLA during the second half of FY26.
Management Guidance and Commentary: * Full-year R&D spend is expected to be at the lower end of the 6%-8% guidance. * The GLP-1 market is considered exciting, and Sun Pharma aims to participate in India when patent expiries allow for generic entry. * The company confirmed its openness to considering further U.S. manufacturing presence. * Sales from generic lenalidomide are expected to be minimal for the remainder of the fiscal year, with the majority realized in the first half. * LEQSELVI's revenue contribution is anticipated to grow throughout the year as payer access improves. * ILUMYA for psoriasis is expected to continue its growth trajectory.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.